A phase I trial of ZD9331, a water-soluble, nonpolyglutamatable, thymidylate synthase inhibitor

Clinical Cancer Research

Volumn 9, Issue 4, 2003, Pages 1313-1322

  Plummer, Ruth ^a,e   Rees, Charlotte ^b   Hughes, Andrew ^a   Beale, Philip ^b   Highley, Martin ^a   Trigo, Jose ^b   Gokul, Sathyarathnarn ^a   Judson, Ian ^b   Calvert, Hilary ^a   Jackman, Ann ^c   Mitchell, Fraser ^c   Smith, Robert ^d   Douglass, Edwin ^d  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d ASTRAZENECA   (United Kingdom)

^e Medical Oncology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; DEOXYURIDINE; FLUOROURACIL; PLEVITREXED; RALTITREXED; THYMIDYLATE SYNTHASE; THYMIDYLATE SYNTHASE INHIBITOR;

ADULT; AGED; ALOPECIA; ARTICLE; BILE DUCT CARCINOMA; BLADDER CANCER; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DOSE CALCULATION; DRUG CLEARANCE; DRUG STRUCTURE; FEMALE; HEAD AND NECK CANCER; HUMAN; KIDNEY CANCER; LETHARGY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SARCOMA; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MODELS, CHEMICAL; NEOPLASMS; QUINAZOLINES; THYMIDYLATE SYNTHASE; TIME FACTORS; WATER;

EID: 0037388241     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Moran, R. G. Roles of folylpoly-γ-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin. Oncol., 26(2 Suppl. 6): 24-32, 1999.
2. Jackman, A. L., and Calvert, A. H. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann. Oncol., 6: 871-881, 1995.
3. Galpin, A. J., Schuetz, J. D., Masson, E., Yanishevski, Y., Synold, T. W., Barredo, J. C., Pui, C. H., Relling, M. V., and Evans, W. E. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: Mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol. Pharmacol., 52: 155-163, 1997.
4. Boyle, F. T., Stephens, T. C., Averbuch, S. D., and Jackman, A. L. ZD9331 Preclinical and clinical studies. In: A. L. Jackman (ed.), Anticancer Drug Development Guide: Antifolate Drugs in Cancer Therapy, pp. 243-260. Totowa, NJ: Humana Press Inc., 1998.
5. Jackman, A. L., Kimbell, R., Aherne, G. W., Brunton, L., Jansen, G., Stephens, T. C., Smith, M. N., Wardleworth, J. M., and Boyle, F. T. Cellular pharmacology and in vitro activity of a new anticancer agent ZD9331: a water-soluble, nonpolyglutamatable quinazoline-based inhibitor of thymidylate synthase. Clin. Cancer Res., 3: 911-921, 1997.
6. Jackman, A. L., Kimbell, R., Brown, M., Brunton, L., Harrap, K. R., Wardleworth, J. M., and Boyle, F. T. The antitumor activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor. Adv. Exp. Med. Biol., 370: 185-188, 1994.
7. Goh, B. C., Ratain, M. J., Bertucci, D., Smith, R., Mani, S., Vogelzang, N. J., Schilsky, R. L., Hutchison, M., Smith, M., Averbuch, S., and Douglass, E. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J. Clin. Oncol., 19: 1476-1484, 2001.
8. Rees, C., Beale, P., Trigo, J., Mitchell, F., Jackman, A., Smith, R., Hutchison, M., Smith, M., Judson, I., and Averbuch, S. Phase I trial of ZD9331, a non-polyglutamatable thymidylate synthase (TS) inhibitor given as a five day continuous infusion every three weeks. Proc. Am. Soc. Clin. Oncol., 18: 171a, 1999.
9. Ratain, M. J., Cooper, N., Smith, R., Vogelzang, N. J., Mani, S., Shulman, K., Lowe, P. G., and Averbuch, S. D. Phase I study of ZD9331: a novel thymidylate synthase (TS) inhibitor. Proc. Am. Soc. Clin. Oncol., 16: 208a, 1997.
10. Mitchell, F., Lynn, S., and Jackman, A. L. Modified high-performance liquid chromatography assay for the measurement of 2′-deoxyuridine in human plasma and its application to pharmacodynamic studies of antimetabolite drugs. J. Chromatogr. B. Biomed. Sci. Appl., 744: 351-358, 2000.
11. Ford, H. E. R., Mitchell, F., Cunningham, D., Farrugia, D. C., Hill, M. E., Rees, C., Calvert, A. H., Judson, I. R., and Jackman, A. L. Patterns of elevation of plasma 2′-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Clin. Cancer Res., 8: 103-109, 2002.
12. de Jonge, M. J. A., Punt, C. J. A., Sparreboom, A., Planting, A. S. T., Peters M. E. J. W., van de Schraaf, J., Jackman, A., Smith, R., de Mulder, P. H. M., and Verweij, J. Phase I and pharmacologic study of oral ZD9331, a novel non-polyglutamated thymidylate synthase (TS) inhibitor, in adult patients with solid tumours. J. Clin. Oncol., 20: 1923-1931, 2002.
13. Diab, S. G., Rha, S. Y., Britten, C., Baker, S. D., Smith, R., Hammond, L., Newman, A., Douglass, E., Von Hoff, D., and Rowinsky, E. Evaluation of the factors influencing clearance of the novel thymidylate synthase inhibitor ZD9331. Eur. J. Cancer, 35: S285, 1999.
14. Rafi, I., Taylor, G. A., Calvete, J. A., Boddy, A. V., Balmanno, K., Bailey, N., Lind, M., Calvert, A. H., Webber, S., and Jackson, R. C. Clinical pharmacokinetic and pharmacodynamic studies with the nonclassical antifolate thymidylate synthase inhibitor 3, 4-dihydro-2-amino-6-methyl-4-oxo-5-(pyridylthio)-quinazoline dihydrochloride (AG337) given by 24 h continuous intravenous infusion. Clin. Cancer Res., 1: 1275-1284, 1995.
15. Rafi, I., Boddy, A. V., Calvete, J. A., Taylor, G. A., Newell, D. R., Bailey, N. P., Lind, M. J., Green, M., Hines, J., Johnstone, A., Clendeninn, N., and Calvert, A. H. Preclinical and phase I clinical studies with the nonclassical antifolate thymidylate synthase inhibitor nolatrexed dihydrochloride given prolonged administration in patients with solid tumors. J. Clin. Oncol., 16: 1131-1141, 1998.
16. Bertucci, D., Smith, R., Mani, S., Vogelzang, N. J., Schilsky, R. L., Goh, B. C., Smith, M., Douglass, E., and Ratain, M. J. A fixed-dose Phase I study of ZD9331, a novel non-polyglutamated inhibitor of thymidylate synthase, in patients with refractory cancer. Eur. J. Cancer, 35: S286, 1999.
17. Schulz, J., and Douglass, E. ZD9331 as second- or third-line therapy in patients with advanced colorectal cancer: a Phase II multicenter trial. Ann. Oncol., 11(Suppl. 4): 62, 2000.
18. Rader, J., Clarke-Pearson, D., Moore, M., Carson, L., Holloway, R., Kao, M-S., Wiznitzer, I., and Douglass, E. Phase II trial of ZD9331 as third-line therapy for patients with ovarian carcinoma. Ann. Oncol., 11(Suppl. 4): 83, 2000.